J Cancer 2016; 7(15):2197-2206. doi:10.7150/jca.16686 This issue

Research Paper

Alteration status and prognostic value of MET in head and neck squamous cell carcinoma

Yoon Ah Cho1, Eun Kyung Kim1, Su Jin Heo2, Byoung Chul Cho2, Hye Ryun Kim2, Ji Myung Chung3, Sun Och Yoon1✉

1. Department of Pathology, Yonsei University College of Medicine, Seoul, Korea;
2. Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea;
3. Yonsei University College of Medicine, Seoul, Korea.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Cho YA, Kim EK, Heo SJ, Cho BC, Kim HR, Chung JM, Yoon SO. Alteration status and prognostic value of MET in head and neck squamous cell carcinoma. J Cancer 2016; 7(15):2197-2206. doi:10.7150/jca.16686. Available from https://www.jcancer.org/v07p2197.htm

File import instruction


The MET pathway plays a key role in various cancers, and its inhibition represents a potential treatment target. However, appropriate biomarkers are needed to facilitate the selection of patients who would benefit from MET inhibiting therapy. We herein conducted a robust confirmatory evaluation of the MET copy number alteration status and prognostic significance of c-Met expression in a large series of patients (n = 396) who underwent standard surgical resection and adjuvant chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC). Surgically resected HNSCC samples were subjected to immunohistochemical and H-score analysis of c-Met expression and silver in situ hybridization analysis of MET amplification and copy number gains. c-Met expression varied, with mean and median H-scores (scale: 0-300 scale) of 61.2 and 60.0, respectively. The lowest and highest expression levels were observed in SCC of the larynx and oral cavity, respectively. MET copy number gains were observed in 16.9% of cases (67/339) and were associated with c-Met protein expression. High c-Met expression, determined according to MET gain status, was associated with an inferior overall survival rate, especially among completely resected cases. In conclusion, our robust analysis revealed that c-Met expression in HNSCCs varied according to anatomical site, correlated with MET copy number gains, and was associated with poor prognosis. This c-Met expression analysis method, which is based on the MET gain status, appears to appropriately predict high-risk HNSCC patients in the context of anti-MET therapeutic decisions.

Keywords: Head and neck squamous cell carcinoma, c-Met protein, MET gene, Prognosis